HLA-mismatched micro-transplantation as post-remission treatment compared to autologous hematopoietic stem cell transplantation or consolidation with single agent cytarabine for favorable-or intermediate-risk acute myeloid leukemia

Article Hematology

Efficacy of conventional-dose cytarabine, idarubicin and thioguanine versus intermediate-dose cytarabine and idarubicin in the induction treatment of acute myeloid leukemia: Long-term results of the prospective randomized nationwide AML-2003 study by the Finnish Leukemia Group

Aarne Kolonen et al.

Summary: The AML-2003 study compared the long-term efficacy and safety of IAT and IdAraC-Ida in induction chemotherapy for AML and emphasized the importance of a treatment strategy guided by integrated genetic and clinical risk classification.

EUROPEAN JOURNAL OF HAEMATOLOGY (2022)

Add to Collection

Article Hematology

Clinical prognostic risk analysis and progression factor exploration of primary breast lymphoma

Jili Deng et al.

Summary: This study analyzed the prognostic risk factors and relapse factors of primary breast diffuse large B cell lymphoma. The main issues we are facing now are local breast and central nervous system recurrence.

HEMATOLOGY (2022)

Add to Collection

Article Oncology

Acute Myeloid Leukemia, Version 2.2021 Featured Updates to the NCCN Guidelines

Daniel A. Pollyea et al.

Summary: The NCCN Guidelines for Acute Myeloid Leukemia provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment. Recent updates focus on familial genetic alterations, treatment strategies for low-risk and favorable-risk AML, venetoclax-based therapies, and considerations for patients who prefer not to receive blood transfusions.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)

Add to Collection

Review Medicine, General & Internal

Advances in acute myeloid leukemia

Laura F. Newell et al.

Summary: AML, a rare and potentially catastrophic diagnosis, has seen recent advancements in personalized therapy and novel treatment options due to discoveries of molecular drivers of the disease.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Review Hematology

High risk of relapse with intermediate dose cytarabine for consolidation in young favourable-risk acute myeloid leukaemia patients following induction with 7+3: a retrospective multicentre analysis and critical review of the literature

Bhaskar C. Kolla et al.

Summary: Following the 2017 ELN guidelines, changing consolidation therapy from high-dose cytarabine to intermediate-dose cytarabine in young, favourable-risk AML patients led to a significantly higher risk of relapse with IDAC compared to HIDAC.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

Add to Collection

Review Oncology

Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma

Alessandra Romano et al.

Summary: This review discussed the current available immunotherapy options in multiple myeloma patients, targeting different antigens such as CD38, SLAMF7, and BCMA. The mechanisms of action, advantages, and disadvantages of these immunotherapeutic approaches were highlighted in the literature data review.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Hematology

Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study

Daniel A. Pollyea et al.

Summary: This study provides the longest-term follow-up analysis for AML patients treated with venetoclax plus azacitidine or decitabine. The results indicate that venetoclax plus hypomethylating agents are highly effective frontline therapies for AML patients unfit for intensive chemotherapy.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

Add to Collection

Article Hematology